The Drug Policy Alliance is the leading organization in the United States working to end the war on drugs, repair its harms, and build a better approach. We envision a just society in which the use and regulation of drugs are grounded in science, compassion, health, and human rights. We fight every day and at every policy level – local, state, federal, and international – to change laws, advance justice, and save lives.
We have helped enact reforms that legalized marijuana for medicinal and adult use, repealed mandatory minimum sentencing and other excessive penalties (such as the Rockefeller Drug Laws in New York), rolled back civil asset forfeiture practices, expanded access to syringes and overdose prevention measures, expunged criminal convictions, reinvested in Black and Brown communities harmed by the drug war, and so much more.
As a result of our advocacy and movement-building efforts, there are tens of thousands fewer people incarcerated, and hundreds of thousands who were not arrested or did not go to jail or prison in the first place, or who spent less time behind bars. Millions more now have access to health services, saving countless lives over the years. Today we have a vibrant and growing movement for reform across multiple intersecting fields.
We have been working toward decriminalizing possession and making it a mainstream political issue for years. Our work is now paying off. Late last year, for the first time ever on a presidential debate stage, front-running candidates spoke about the need to decriminalize the personal possession of all drugs – not just marijuana. The validation of all-drug decriminalization in such a high-profile political moment demonstrates how far – and fast – we have moved.
Beyond our cutting-edge work on decriminalizing possession, over the last year we have had multiple first-time victories.
In November, the U.S. House of Representatives’ Judiciary Committee approved the MORE Act – the first comprehensive marijuana legalization bill to be approved by a congressional committee. The MORE Act would de-schedule marijuana at the federal level, expunge past criminal records, and begin to repair the harms of prohibition in the communities where it has been most viciously enforced. DPA worked closely with the bill’s sponsors to shape the legislation and build bipartisan support.
In another first, in June, the House passed a bipartisan amendment to the appropriations bill that would prevent the Department of Justice from interfering in states that have legalized marijuana for adult use. Not only that, the amendment passed by a landslide 276-165 vote – the result of many years of relentless advocacy by our national affairs team in Washington, D.C.
There were more than 68,000 overdose deaths in the United States in 2018.
How do you explain harm reduction to people who aren’t familiar with the term?
Harm reduction is about meeting people where they are – whether they use drugs, experience homelessness, or live with HIV – to give them the tools to help themselves and their community. I didn’t save any of the thousands of lives that have been saved in South Florida. That was people in the community saving each other’s lives.
Why is it critical to focus on harm reduction in the South?
Most new HIV infections in our country take place in the South, but we’re denying the majority of the region basic public health measures. We know providing sterile syringes can decrease the HIV rate by 80 percent, so if we withhold this service from vulnerable people, it says we do not value their lives.
What other benefits have you seen from the program’s expansion?
For decades, there was no mechanism for people experiencing homelessness and who use drugs to get into any sort of care in Miami. Now they can access sterile syringes and naloxone, see a doctor, and receive HIV testing. They are treated with dignity and respect by people who want to work with them.
What do you see as the value that DPA added to the whole process?
DPA was instrumental in complex political maneuvering in Tallahassee – helping with the overall strategy and with drafting the bill language. DPA also invested in lobbying power in the capital and helped us strategize and troubleshoot to keep the bill advancing.
How do you feel about the drug education curricula that you’ve taught in the past?
The guidance previously offered to us has basically been an abstinence-only approach. It was suggesting you don’t need to teach people any facts about drugs as long as you tell them not to use drugs.
How do the old materials you were using compare to using Safety First in your classroom?
Safety First is mind-expanding. As a non-drug user, I don’t have much knowledge about drugs, but Safety First gave me all kinds of guidance to share with students that made them feel empowered, that made them feel like they could not only help themselves but help other people. I really loved the fact that we look at our young people not as problems to be solved, but as potential heroes.
Often in the past, students would be afraid to come forward and talk about issues with either their own or family drug use, but Safety First was nonjudgmental and really opened the conversation. It made us able to process these issues together.
Do you feel like adults are ready to change the way that we educate young people about drugs and drug use?
Ready or not, we have to be there for the students. There’s a crisis in this country. There are people dying of overdoses and misinformation is not helping. We need to be able to have that conversation. And if it’s painful, it’s painful. I don’t care – we have to do it. As a health teacher, I believe that it’s the things that you don’t talk about that have the potential to harm you. If you can talk about it, you take power over it.
DPA is at the forefront of the movement to legalize marijuana nationwide. We are currently leading legalization campaigns in New York and New Mexico, with bills that include a range of provisions to repair the harms of decades of prohibition and unequal enforcement.
Only two years ago, Gov. Andrew Cuomo was firmly against marijuana legalization. DPA’s multiyear campaign played a pivotal role in moving him into the support column and making legalization a key issue in the 2019 legislative session. In June, after a major surge in our campaign that brought the issue back from the dead, we came within days, if not hours, of victory.
While we did not achieve our ultimate goal – creating a responsible legal market for adult use and righting the wrongs of the decades of unequal enforcement – we made sure that the critical incremental reform that was passed codified record expungement for the first time in the state’s history, which will impact upward of 500,000 New Yorkers arrested for low-level marijuana possession. We also moved groundbreaking legislation through the New York City Council to ban marijuana drug testing in the job hiring process and remove marijuana as a reason to revoke probation – local laws that will have national reverberations.
DPA also made significant progress in New Mexico. The state’s House of Representatives approved a bill that would have legalized marijuana for adult use, but it stalled in the Senate. But, with a resounding majority, the legislature went on to pass a bill that decriminalized the first-time possession of up to half an ounce of marijuana, and all drug paraphernalia. After the session, New Mexico Governor Michelle Lujan Grisham
established the Legalization Task Force and appointed DPA’s NM State Director to it. In October, the Task Force published recommendations, including expunging marijuana possession convictions, allowing people with previous drug convictions to participate in the marijuana industry, and dedicating revenue to helping communities and small businesses access capital needed to start and grow businesses.
In Mississippi, DPA is supporting a 2020 ballot initiative to legalize access to medical marijuana, an important step forward in a region where people still receive harsh sentences for simple marijuana possession. In November, activists had collected enough signatures to qualify the initiative to appear on the 2020 ballot.
Influencing Federal Legislation
In November, the House Judiciary Committee voted to approve the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act). The Act would both deschedule marijuana and take critical steps towards repairing harms caused by marijuana prohibition, including:
In addition, the MORE Act establishes an Opportunity Trust Fund that would provide monies toward reparative and social good measures, including:
The MORE Act is the first piece of comprehensive marijuana legislation to ever make it out of a congressional committee, and is set to be the first to ever receive a floor vote.
We also made history this year when the U.S. House of Representatives overwhelmingly passed the Blumenauer-McClintock-Norton amendment, which would have prevented the Department of Justice from interfering in states that have legalized marijuana for adult use. This had been decades in the making, with DPA leading the charge, and was the first time marijuana legalization had been affirmed in Congress. While the amendment was not approved by the Senate, we are now working on several other bills in Congress to end prohibition in a just and equitable way. Until the federal prohibition on marijuana falls, we are committed to blocking federal interference with state’s marijuana policies.
Cash & cash equivalents | $ | 94,894 |
Investments | $ | 383,181 |
Accounts receivable | $ | 17,472 |
Grants receivable (net) | $ | 3,629,846 |
Prepaid expenses & other assets | $ | 86,172 |
Deposits | $ | 111,700 |
Property, equipment & leasehold improvements (net) | $ | 4,947,801 |
Total Assets |
$ |
9,271,066 |
Accounts payable & accrued expenses | $ | 146,437 |
Accrued compensated absences | $ | 295,294 |
Mortgage payable | $ | 2,536,988 |
Total Liabilities | $ | 2,978,719 |
Unrestricted | $ | 2,157,911 |
Temporarily restricted | $ | 4,134,436 |
Total Net Assets | $ | 6,292,347 |
Program expenses | $ | 9,786,179 |
Management | $ | 2,813,723 |
Fundraising | $ | 1,805,913 |
Total Expenses |
$ |
14,405,815 |
Contributions unrestricted | $ | 13,965,242 |
Contributions temporarily restricted | $ | (715,556) |
Total Income |
$ |
13,249,686 |
Unrestricted | $ | 12,104,191 |
Temporarily restricted | $ | (647,153) |
Net assets, beginning of year | $ | (5,164,691) |
Net assets, end of year | $ | 6,292,347 |
Cash & cash equivalents | $ | 8,844,800 |
Investments | $ | 6,661,332 |
Grants receivable (net) | $ | 7,753,096 |
Total Assets |
$ |
23,259,228 |
Accounts payable & accrued expenses | $ | 17,472 |
Unrestricted | $ | 15,388,660 |
Temporarily restricted | $ | 7,853,096 |
Total Net Assets | $ | 23,241,756 |
Several Drug Policy Alliance and Drug Policy Action donors have made multi-year pledges to these organizations. These unfulfilled pledges are projected future revenue that will be received within one to nine years and does not constitute an endowment. These donor commitments reflect a strong current and future financial outlook for the Drug Policy Alliance and Drug Policy Action.
Program expenses | $ | 6,736,880 |
Management | $ | 240,083 |
Fundraising | $ | 2,311 |
Total Expenses |
$ |
6,979,274 |
Contributions unrestricted | $ | 4,269,254 |
Contributions temporarily restricted | $ | (2,245,399) |
Total Income |
$ |
2,023,855 |
Unrestricted | $ | (2,710,020) |
Temporarily restricted | $ | (2,245,399) |
Net assets, beginning of year | $ | 28,197,175 |
Net assets, end of year | $ | 23,241,756 |
Drug Policy Alliance Headquarters
131 West 33rd Street, 15th Floor
New York, NY 10001
212.613.8020 phone
contact@drugpolicy.org